[Application of anti-resorptive drugs for the treatment of osteoporosis].
The applications of anti-resorptive drugs for the treatment of osteoporosis were reviewed. The aging, low bone mineral density, increased bone turnover, and prevalent fracture were risk factors for new fracture. Bisphosphonates (alendronate and risedronate) and raloxifene showed a significant reduction in relative risk for vertebral fractures. On the other hand, alendronate and risedronate were the only two therapies that had a significant pooled treatment effects on nonvertebral fracture reduction. Hip fractures in Japan increase in the age of 70 years and over. This etiology indicates that bisphosphonate might be suitable for the patients who were 70 years of age and over. There was no significant difference between alendronate and risedronate in the efficacy of the decrease of bone resorption marker.
Takada
Junichi
J
Department of Orthopedic Surgery, Chitose City Hospital.
D000368:Aged; D019386:Alendronate / Q000627:therapeutic use; D001862:Bone Resorption / Q000188:drug therapy*; D004164:Diphosphonates / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D000068296:Risedronic Acid
D004164:Diphosphonates; D020849:Raloxifene Hydrochloride; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate